1603 GMT - The results of a U.S. probe into the pharmaceutical sector are imminent, but any potential hits from President Trump's tariffs and drug-price policies seem to be already priced in by Swiss pharma stocks, Vontobel's Stefan Schneider says in a note. Vontobel estimates U.S. drug prices could be cut by between 5% and 33%, but finds that this is already factored into Swiss pharma stock prices. According to Vontobel's analysis, Roche shares could see a movement from 0% in its base-case scenario to a 7% drop in its worst-case scenario, while Novartis shares could either rise or fall by 8%. This means the outcome of the U.S. investigation could also trigger share-price rises as a clearer picture emerges, the analyst says. Shares in Novartis and Roche close 0.9% and 0.4% lower, respectively. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
August 22, 2025 12:03 ET (16:03 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.